Department of Biochemistry & Molecular Biology, University of Oklahoma Health Science Center, Oklahoma City, Oklahoma 73104, USA.
Cancer Invest. 2012 Feb;30(2):189-97. doi: 10.3109/07357907.2011.636115. Epub 2011 Dec 7.
Sera mass spectrometry (MS) peak differences were analyzed from 35 ovarian cancer patients and 16 disease-free individuals. "Leave one out" cross validation was used to assign "% cancer peaks" in control and ovarian cancer sera samples. Sera MS discriminated stage I/II and stage III/V ovarian cancer patients versus controls with ROC curve area values of 0.82 and 0.92. Test sensitivities for ovarian cancer stage I/II and III/V were 80% and 93% respectively. These results indicate that MS is useful for distinguishing sera from early-stage ovarian cancer patients, and has potential as a test for early detection of this disease.
对 35 名卵巢癌患者和 16 名无病个体的血清质谱 (MS) 峰差异进行了分析。采用“留一法”交叉验证将“%癌症峰”分配给对照和卵巢癌血清样本。血清 MS 通过 ROC 曲线面积值为 0.82 和 0.92 区分了 I/II 期和 III/V 期卵巢癌患者与对照组。卵巢癌 I/II 期和 III/V 期的检测灵敏度分别为 80%和 93%。这些结果表明，MS 可用于区分早期卵巢癌患者的血清，并具有作为该疾病早期检测的潜在用途。
